Skip to main content
FHTX
NASDAQ Life Sciences

Foghorn Halts FHD-909 and SMARCA2 Programs, Cuts 40% of Workforce

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$3.57
Mkt Cap
$212.006M
52W Low
$3.27
52W High
$7.61
52W Position info
9.2% above low
Off High info
53% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

FHTX is trading near its 52-week low of $3.27 (9.2% above the low).

Summary

Foghorn Therapeutics and Lilly are discontinuing the FHD-909 and SMARCA2 programs, and Foghorn is cutting 40% of its workforce to focus on its proprietary pipeline, extending cash runway into 2029. Foghorn shares fell 27.17% to $2.60, a new 52-week low, on volume of 9.158 million.

Updated with a Benzinga report · What changed

Updates

  1. · Benzinga — Foghorn shares fell 27.17% to $2.60, a new 52-week low, on volume of 9.158 million.

    • FHD-909's Lilly internal designation is LY4050784.
    • Foghorn will prioritize a Selective EP300 degrader, an oral immunology and inflammation program, a Selective CBP degrader, and its induced proximity platform.
    • The 2021 collaboration with Lilly included a selective BRM program, an undisclosed program, and three discovery programs using the Gene Traffic Control platform.

Key Events · Product Development and Regulatory · FHTX

  • New · · Benzinga

    Stock Price Decline

    Foghorn shares fell 27.17% to $2.60, a new 52-week low, on volume of 9.158 million.

  • New · · Benzinga

    Pipeline Prioritization

    Foghorn will prioritize a Selective EP300 degrader, an oral immunology and inflammation program, a Selective CBP degrader, and its induced proximity platform.

  • New · · Benzinga

    2021 Lilly Collaboration Details

    The 2021 collaboration with Lilly included a selective BRM program, an undisclosed program, and three discovery programs using the Gene Traffic Control platform.

  • Updated · · Benzinga

    FHD-909 Program Discontinued

    After reviewing clinical data, Foghorn and Lilly will not advance the Phase 1 trial of FHD-909 into the expansion phase. The Selective SMARCA2 degrader program is also being discontinued. FHD-909's Lilly internal designation is LY4050784.

  • Lilly Collaboration Winding Down

    The companies do not anticipate further collaboration activities, ending a key partnership for Foghorn.

  • 40% Workforce Reduction

    The Board approved a strategic reprioritization on September 30, 2026, reducing the workforce by approximately 40% to about 65 full-time employees, with completion expected in Q4 2026.

  • Restructuring Charges

    Foghorn estimates aggregate charges of approximately $2.3 million, primarily for one-time employee severance and benefit costs, to be incurred in Q4 2026.


Analysis · FHTX · Life Sciences

A major setback for the company's lead partnered program and a significant strategic pivot: Foghorn Therapeutics and Eli Lilly have decided not to advance the Phase 1 trial of FHD-909 into the expansion phase, and the collaboration will also not advance the Selective SMARCA2 degrader program. The company is now prioritizing its wholly owned pipeline and reducing its workforce by approximately 40%, leaving about 65 employees. The restructuring is expected to extend cash runway into the second half of 2029, with one-time charges of approximately $2.3 million for severance and benefits. FHD-909's Lilly internal designation is LY4050784. Foghorn will prioritize a Selective EP300 degrader, an oral immunology and inflammation program, a Selective CBP degrader, and its induced proximity platform. The 2021 collaboration with Lilly included a selective BRM program, an undisclosed program, and three discovery programs using the Gene Traffic Control platform. Foghorn shares fell 27.17% to $2.60, a new 52-week low, on volume of 9.158 million.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, FHTX was trading at $3.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $212M. The 52-week trading range was $3.27 to $7.61. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

FHTX - Latest Insights

FHTX
Nov 09, 2026, 7:31 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.87
Real-time Price: $2.07 info
Change: +$0.200 (+11%) info
Market Cap: $124.123M info
FHTX
Nov 09, 2026, 7:06 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.87
Real-time Price: $2.07 info
Change: +$0.200 (+11%) info
Market Cap: $124.123M info
FHTX
Oct 01, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $3.57
Real-time Price: $2.07 info
Change: -$1.50 (-42%) info
Market Cap: $124.123M info
FHTX
May 07, 2026, 7:11 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.68
Real-time Price: $2.07 info
Change: -$2.61 (-56%) info
Market Cap: $124.123M info
FHTX
May 07, 2026, 7:02 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.68
Real-time Price: $2.07 info
Change: -$2.61 (-56%) info
Market Cap: $124.123M info